

Jennifer N Durham

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1963302/jennifer-n-durham-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

3,961
citations

13
h-index

17
g-index

17
ext. papers

5,403
ext. citations

13.4
avg, IF

4.27
L-index

#	Paper	IF	Citations
17	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1278-1286	12.9	11
16	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. <i>Cancer Cell</i> , 2021 , 39, 973-988	12.9	13
15	Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. <i>Nature Cancer</i> , 2021 , 2, 891-903	15.4	18
14	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5129-5139	12.9	28
13	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3578-3588	12.9	36
12	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020 , 11, 1929-1941	3.3	3
11	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020 , 9, 1485-1494	4.8	25
10	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3182-3192	12.9	31
9	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019 , 7, 1574-1579	12.5	21
8	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 5250-5259	12.9	29
7	A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. <i>Cancer</i> , 2019 , 125, 2837-2845	6.4	8
6	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019 , 364, 485-491	33.3	228
5	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3546-3555	2.2	32
4	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 2019 , 7, 40		28
3	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2019 , 25, 7024-7034	12.9	48
2	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2018 , 3,	9.9	128
1	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017 , 357, 409-413	33.3	3274

